Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077064 · ClinicalTrials.gov registry record · Phase 2
Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00077064 is a Phase 2 study that was terminated before completion, run by Radiation Therapy Oncology Group. The registered enrollment target is 81 participants.
The verdict
NCT00077064, a Phase 2 study, was terminated before completion, sponsored by Radiation Therapy Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works in decreasing side effects and improving the quality of life in patients who have received radiation therapy with or without chemotherapy for stage I, stage II, or stage IIIB non-small cell lung cancer or limited-stage small cell lung cancer.
Interventions
- DRUG captopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2003-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077064
The ClinicalTrials.gov registry entry for NCT00077064 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which captopril is the first listed.
NCT00077064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077064 about?
NCT00077064 is a clinical study titled "Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy". RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works...
What is the current status of trial NCT00077064?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2003-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT00077064?
The interventions under investigation include: captopril (DRUG).
Who is sponsoring clinical trial NCT00077064?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.